NITREX NITINOL GUIDEWIRE

K031864 · Ev3 Corporation · DQX · Jun 24, 2003 · Cardiovascular

Device Facts

Record IDK031864
Device NameNITREX NITINOL GUIDEWIRE
ApplicantEv3 Corporation
Product CodeDQX · Cardiovascular
Decision DateJun 24, 2003
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 870.1330
Device ClassClass 2

Intended Use

The 0.035'' and 0.025'' Guidewire is indicated for use in the peripheral vasculature. The 0.014'', 0.016'', and 0.018'' guidewires are indicated for use in the peripheral and coronary vasculature.

Device Story

Nitinol (nickel-titanium alloy) guidewire; distal tip features helically coiled gold-plated tungsten wire; surface coating facilitates smooth passage. Used by clinicians in peripheral and coronary vasculature procedures to assist in catheter placement. Device provides mechanical support and navigation through vascular anatomy. Benefits include improved trackability and access to target vessels.

Clinical Evidence

Bench testing only. Dimensional inspection conducted with acceptable results; verification/validation testing confirmed modifications do not impact original device performance.

Technological Characteristics

Materials: Nitinol (nickel-titanium alloy) core, gold-plated tungsten wire distal coil. Surface coating applied. Dimensions: 0.014", 0.016", 0.018", 0.025", and 0.035" diameters. Mechanical device; no energy source or software.

Indications for Use

Indicated for use in peripheral vasculature (0.035", 0.025", 0.014", 0.016", 0.018" diameters) and coronary vasculature (0.014", 0.016", 0.018" diameters).

Regulatory Classification

Identification

A catheter guide wire is a coiled wire that is designed to fit inside a percutaneous catheter for the purpose of directing the catheter through a blood vessel.

Special Controls

*Classification.* Class II (special controls). The device, when it is a torque device that is manually operated, non-patient contacting, and intended to manipulate non-cerebral vascular guide wires, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo for EV3. The logo consists of three circles arranged in a triangular pattern above the letters "ev3" in a stylized font. The circles are solid black, and the letters are also black. PH 763 398 7000 FX 763.398.7200 4600 Nathan Lane North, Plymouth, MN 55442-2920 ## 10(k) Summary The 510(k) Summary is submitted in accordance with 21 CFR Part 807, Section 807.92 | Submitter | EV3 | |------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 4600 NATHAN LANE NORTH<br>PLYMOUTH, MN 55442 | | TRADE NAME | Nitrex™ Nitinol Guidewire | | GENERIC CLASS | Guide wire | | CLASSIFICATION | Class II (21 CFR 870.1330) | | SUBMITTED BY | ev3 Inc<br>4600 Nathan Lane<br>Minneapolis, MN 55442 | | CONTACT | Carolyn Anderson<br>Regulatory Affairs Specialist<br>763-398-7487 | | PREDICATE | Ultra-Select guidewire (K910280)<br>FlexFinder guidewire (K893626, K943390)<br>Nitrex Nitinol Guidewire (K024021) | | DEVICE<br>DESCRIPTION | The guidewire is constructed of nitinol (nickel-titanium alloy).<br>The nitinol core extends from the distal tip of the guidewire to the<br>proximal shaft end. The distal tip is a helically coiled coil gold<br>plated tungsten wire. The guidewire is coated with a coating(s)to<br>help facilitate smooth passage. | | INDICATION FOR<br>USE | The 0.035" and 0.025" Guidewire is indicated for use in the<br>peripheral vasculature. The 0.014", 0.016", and 0.018" guidewires<br>are indicated for use in the peripheral and coronary vasculature. | | TESTING | Dimensional inspection of the guidewire has been conducted. All<br>testing of the product yielded acceptable results. A review of the<br>verification/validation testing performed on the original device<br>determined that the modification would not affect the original<br>results. | | SUMMARY OF<br>SUBSTANTIAL<br>EQUIVALENCE | The Nitrex™ Nitinol Guidewire is substantially equivalent to the<br>predicate device in intended use, materials, labeling and principles<br>of operation | Image /page/0/Picture/9 description: The image shows the logo for EV3, which is a robotics kit. The logo consists of the letters "ev3" in lowercase, with three circles arranged in a triangular pattern above the letters. The letters and circles are all in black, and the background is white. {1}------------------------------------------------ Image /page/1/Picture/2 description: The image shows the logo for the Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES" written around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right. The profiles are stacked on top of each other, with the top profile being the most prominent. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUN 2 4 2003 EV3 Corporation c/o Ms. Carolyn Anderson Regulatory Affairs Specialist 4600 Nathan Lane Plymouth, MN 55442 Re: K031864 Nitrex™ Nitinol Guidewire Regulation Number: 21 CFR 870.1330 Regulation Name: Wire, Guide, Catheter Regulatory Class: Class II (two) Product Code: DQX Dated: June 13, 2003 Received: June 16, 2003 Dear Ms. Anderson: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {2}------------------------------------------------ Page 2 - Ms. Carolyn Anderson Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4648. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely vours. C. Mefcal mayn Bram Zuckerman. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## INDICATIONS FOR USE STATEMENT 510 (k) Number (if known): K031864 Device Name: Nitrex™ Nitinol Guidewire Indications For Use: The 0.035'' and 0.025'' Guidewire is indicated for use in the peripheral vasculature. The 0.014'', 0.016'', and 0.018'' guidewires are indicated for use in the peripheral and coronary vasculature. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Mella Mynl for B. Zuckerman 510(k) Number K031864 Prescription Use (Per 21 CFR 801.109) OR Over-the-Counter_
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...